Definitive Healthcare Corp. (NASDAQ:DH) Stock Has Consensus Price Target of $1.47 According to Brokerages

Definitive Healthcare Corp. (NASDAQ:DH) has earned an average recommendation of “Reduce” from the nine analysts that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $1.47.

A number of analysts have commented on DH shares. Morgan Stanley reduced their target price on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating for the company in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $1.00 price target on shares of Definitive Healthcare in a report on Wednesday, August 12th. BTIG Research reiterated a “neutral” rating on shares of Definitive Healthcare in a research note on Friday, September 4th. Weiss Ratings raised shares of Definitive Healthcare from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Finally, Wall Street Zen raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a report on Sunday, September 13th.

Definitive Healthcare Price Performance

DH opened at $1.19 on Wednesday. The firm has a market cap of $127.52 million, a PE ratio of 28.00, a P/E/G ratio of 13.82 and a beta of 1.40. The stock has a 50-day moving average price of $1.03 and a 200-day moving average price of $1.05. Definitive Healthcare has a 1 year low of $0.61 and a 1 year high of $3.00. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.86 and a quick ratio of 1.86.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Definitive Healthcare had a negative net margin of 69.18% and a positive return on equity of 4.07%. The firm had revenue of $54.65 million for the quarter, compared to the consensus estimate of $54.58 million. Sell-side analysts predict that Definitive Healthcare will post 0.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. bought a new position in Definitive Healthcare in the 3rd quarter worth $90,000. Williams & Novak Wealth Management LLC lifted its holdings in Definitive Healthcare by 15.3% during the third quarter. Williams & Novak Wealth Management LLC now owns 90,610 shares of the company’s stock valued at $82,000 after purchasing an additional 12,000 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in Definitive Healthcare by 46.5% during the second quarter. Squarepoint Ops LLC now owns 351,575 shares of the company’s stock valued at $292,000 after purchasing an additional 111,634 shares in the last quarter. Corient Private Wealth LP bought a new position in shares of Definitive Healthcare in the second quarter worth approximately $378,000. Finally, Williams & Novak LLC boosted its position in shares of Definitive Healthcare by 155.8% in the second quarter. Williams & Novak LLC now owns 78,610 shares of the company’s stock worth $65,000 after purchasing an additional 47,880 shares during the period. 98.67% of the stock is currently owned by institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare Corp. (NASDAQ: DH) provides data, analytics and commercial intelligence solutions for the healthcare industry. Its platform is designed to help organizations understand healthcare markets, identify business opportunities and make data-driven decisions. The company serves pharmaceutical and biotechnology companies, medical device manufacturers, healthcare providers, hospitals and health systems, and other healthcare services organizations. Its offerings include information on healthcare providers and organizations, market intelligence, sales and marketing analytics, clinical trial insights, and tools that support commercial planning, market access and customer engagement.